10X Genomics Inc
TXG11.990USD
+0.070+0.59%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.48BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über 10X Genomics Inc Unternehmen
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Unternehmensinformationen
BörsenkürzelTXG
Name des Unternehmens10X Genomics Inc
IPO-datumSep 12, 2019
Gegründet am2012
CEOMr. Serge Wilson Saxonov, Ph.D.
Anzahl der mitarbeiter1306
WertpapierartOrdinary Share
GeschäftsjahresendeSep 12
Addresse6230 Stoneridge Mall Road
StadtPLEASANTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94588
Telefon19254017300
Websitehttps://www.10xgenomics.com/
BörsenkürzelTXG
IPO-datumSep 12, 2019
Gegründet am2012
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.07M
-0.09%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+4.34%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+29.09%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+34.83%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
52.17K
-12.55%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+115.82%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
28.62K
+115.82%
Mr. Adam S. Taich
Mr. Adam S. Taich
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alan V. Mateo
Mr. Alan V. Mateo
Independent Director
Independent Director
--
--
Dr. Sarah A. Teichmann
Dr. Sarah A. Teichmann
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.07M
-0.09%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+4.34%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+29.09%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+34.83%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
52.17K
-12.55%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+115.82%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables
115.36M
74.48%
Products and services revenue
17.06M
11.01%
Instruments
14.81M
9.57%
Services
7.65M
4.94%
Nach RegionUSD
Name
Umsatz
Anteil
United States
86.82M
56.05%
Europe, the Middle East and Africa
31.89M
20.59%
China
16.88M
10.90%
Asia Pacific
15.54M
10.03%
Americas
3.75M
2.42%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables
115.36M
74.48%
Products and services revenue
17.06M
11.01%
Instruments
14.81M
9.57%
Services
7.65M
4.94%
Aktionärsstatistik
Aktualisiert: Fri, May 23
Aktualisiert: Fri, May 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
ARK Investment Management LLC
11.56%
The Vanguard Group, Inc.
9.99%
Fidelity Management & Research Company LLC
7.72%
Millennium Management LLC
4.98%
BlackRock Institutional Trust Company, N.A.
4.87%
Other
60.88%
Aktionäre
Aktionäre
Anteil
ARK Investment Management LLC
11.56%
The Vanguard Group, Inc.
9.99%
Fidelity Management & Research Company LLC
7.72%
Millennium Management LLC
4.98%
BlackRock Institutional Trust Company, N.A.
4.87%
Other
60.88%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
45.04%
Investment Advisor/Hedge Fund
22.18%
Hedge Fund
19.03%
Bank and Trust
5.32%
Research Firm
5.16%
Venture Capital
3.69%
Individual Investor
1.92%
Pension Fund
0.68%
Family Office
0.30%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
656
115.46M
103.93%
-12.51M
2025Q1
687
115.67M
104.27%
-8.84M
2024Q4
689
107.08M
98.92%
-12.41M
2024Q3
682
106.90M
100.39%
-9.08M
2024Q2
691
105.36M
99.70%
-5.09M
2024Q1
762
106.36M
101.17%
-3.12M
2023Q4
817
100.80M
96.01%
-9.73M
2023Q3
835
96.86M
93.80%
-12.55M
2023Q2
857
94.98M
96.77%
-15.37M
2023Q1
864
95.62M
97.55%
-9.91M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
ARK Investment Management LLC
12.85M
11.56%
+901.66K
+7.55%
Mar 31, 2025
The Vanguard Group, Inc.
11.09M
9.99%
+184.54K
+1.69%
Mar 31, 2025
Fidelity Management & Research Company LLC
8.58M
7.72%
-2.75M
-24.30%
Mar 31, 2025
Millennium Management LLC
5.53M
4.98%
+156.13K
+2.90%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
5.41M
4.87%
-108.37K
-1.96%
Mar 31, 2025
Sumitomo Mitsui Trust Bank, Limited
5.36M
4.83%
+5.36M
--
Mar 31, 2025
UBS Asset Management (Switzerland)
4.10M
3.69%
+2.13M
+108.14%
Mar 31, 2025
Two Sigma Investments, LP
3.17M
2.85%
+614.32K
+24.04%
Mar 31, 2025
UBS Asset Management (Americas) LLC
2.90M
2.61%
+2.85M
+4.95K%
Mar 31, 2025
BofA Global Research (US)
2.56M
2.3%
+2.03M
+386.97%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
ARK Genomic Revolution ETF
3.47%
ARK Innovation ETF
1.55%
WisdomTree BioRevolution Fund
1.48%
Global X Genomics & Biotechnology ETF
1.35%
Invesco NASDAQ Future Gen 200 ETF
0.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.36%
ProShares Ultra Nasdaq Biotechnology
0.15%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Biotechnology ETF
0.1%
Goldman Sachs Innovate Equity ETF
0.08%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil3.47%
ARK Innovation ETF
Anteil1.55%
WisdomTree BioRevolution Fund
Anteil1.48%
Global X Genomics & Biotechnology ETF
Anteil1.35%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil0.36%
ProShares Ultra Nasdaq Biotechnology
Anteil0.15%
Invesco Nasdaq Biotechnology ETF
Anteil0.11%
iShares Biotechnology ETF
Anteil0.1%
Goldman Sachs Innovate Equity ETF
Anteil0.08%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
